Reducing Multi-Cycle Reviews Is FDA Priority

Reducing Multi-Cycle Reviews Is FDA Priority
FDA Commissioner Mark McClellan today described key steps the agency is taking to shorten drug approval times, in his keynote speech at IIR�s Phases conference in Washington, D.C.


Comments are closed.

Do NOT follow this link or you will be banned from the site!
Get email updates

Get new actionable insights and updates from BiotechBlog